Isolated from seawater, deuterium is a naturally occurring stable isotope of hydrogen that carries an additional neutron, and it is sometimes known as "heavy hydrogen." Concert Pharmaceuticals Inc. is using the properties of deuterium to create therapeutics based on existing drugs. Adding it to a compound can modify metabolism and create new applications and intellectual property, which Concert feels will enable it to develop highly differentiated medicines more quickly and at lower risk of failure. The company's lead candidate, the HIV protease inhibitor CTP-518, is a deuterium-modified version of Bristol-Myers Squibb's atazanavir.
99 Hayden Avenue
Suite 500
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.
The UK firm's chronic obstructive pulmonary drug Ohtuvayre has been enjoying a stellar launch.
From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.
